Salvatore Battaglia

Salvatore Battaglia

Auto-generated profile, based on publicly available information

Salvatore Battaglia

Department of Economics Business and Statistics, University of Palermo, Palermo, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
Giuseppe CabibboGiuseppe Cabibbo
Giuseppe Cabibbo
CCCiro Celsa
Ciro Celsa
SBSalvatore Battaglia
Salvatore Battaglia
MEMarco Enea
Marco Enea
GMGabriele Di Maria
Gabriele Di Maria
CCCalogero Cammà
Calogero Cammà
Purpose: The prognosis of patients with unresectable hepatocellular carcinoma (HCC) and compensated cirrhosis is influenced by cancer progression. Data on the incidence and the prognostic role of clinical hepatic decompensation (CHD) following immune checkpoint inhibitor therapy are lacking. We aimed to assess whether early CHD within 3 months from commencement of systemic therapy affects overall survival (OS) of patients treated with atezolizumab plus bevacizumab or sorafenib. Patients and Methods: Individual patient data from the IMbrave150 trial were analyzed. Cumulative incidence of CHD was assessed by competing risk analysis against HCC radiologic progression. Early CHD and HCC radiologic progression were assessed as predictors of OS by the time-dependent Cox model. Results: The 3- and 12-month rates of CHD were 7% and 12%, respectively, whereas the 3- and 12-month rates of HCC radiologic progression were 23% and 52%, respectively. Albumin–bilirubin grade 2 [subdistribution HR (sHR) = 1.79, 95% confidence interval (CI), 1.01–3.19; P = 0.049], INR (sHR = 1.97, 95% CI, 1.64–2.37; P < 0.001), and presence of neoplastic macrovascular invasion (sHR = 2.01, 95% CI, 1.14–3.54; P = 0.020) were independently associated with higher risk of CHD. Early CHD (HR = 7.56, 95% CI, 4.47–12.8) and early HCC radiologic progression (HR = 5.92, 95% CI, 4.03–8.69), as first events, were independently associated with higher mortality. Conclusions: This study provides robust evidence that early CHD is associated with the highest risk of death in patients with unresectable HCC undergoing systemic treatment. Within well-compensated participants, albumin–bilirubin, INR, and macrovascular invasion identify a population at higher risk of decompensation. Inclusion of clinical decompensation events in future prospective clinical trials may improve characterization of OS from systemic therapy of HCC.

3 February 2025
Verified
Other
Open access
Giuseppe CabibboGiuseppe Cabibbo
Giuseppe Cabibbo
CCCiro Celsa
Ciro Celsa
SBSalvatore Battaglia
Salvatore Battaglia
MEMarco Enea
Marco Enea
GMGabriele Di Maria
Gabriele Di Maria
CCCalogero Cammà
Calogero Cammà
Supplementary Table 1. Representativeness of Study Participants.

3 February 2025
Verified
Other
Open access
Giuseppe CabibboGiuseppe Cabibbo
Giuseppe Cabibbo
CCCiro Celsa
Ciro Celsa
SBSalvatore Battaglia
Salvatore Battaglia
MEMarco Enea
Marco Enea
GMGabriele Di Maria
Gabriele Di Maria
CCCalogero Cammà
Calogero Cammà
Purpose:The prognosis of patients with unresectable hepatocellular carcinoma (HCC) and compensated cirrhosis is influenced by cancer progression. Data on the incidence and the prognostic role of clinical hepatic decompensation (CHD) following immune checkpoint inhibitor therapy are lacking. We aimed to assess whether early CHD within 3 months from commencement of systemic therapy affects overall survival (OS) of patients treated with atezolizumab plus bevacizumab or sorafenib.Patients and Methods:Individual patient data from the IMbrave150 trial were analyzed. Cumulative incidence of CHD was assessed by competing risk analysis against HCC radiologic progression. Early CHD and HCC radiologic progression were assessed as predictors of OS by the time-dependent Cox model.Results:The 3- and 12-month rates of CHD were 7% and 12%, respectively, whereas the 3- and 12-month rates of HCC radiologic progression were 23% and 52%, respectively. Albumin–bilirubin grade 2 [subdistribution HR (sHR) = 1.79, 95% confidence interval (CI), 1.01–3.19; P = 0.049], INR (sHR = 1.97, 95% CI, 1.64–2.37; P < 0.001), and presence of neoplastic macrovascular invasion (sHR = 2.01, 95% CI, 1.14–3.54; P = 0.020) were independently associated with higher risk of CHD. Early CHD (HR = 7.56, 95% CI, 4.47–12.8) and early HCC radiologic progression (HR = 5.92, 95% CI, 4.03–8.69), as first events, were independently associated with higher mortality.Conclusions:This study provides robust evidence that early CHD is associated with the highest risk of death in patients with unresectable HCC undergoing systemic treatment. Within well-compensated participants, albumin–bilirubin, INR, and macrovascular invasion identify a population at higher risk of decompensation. Inclusion of clinical decompensation events in future prospective clinical trials may improve characterization of OS from systemic therapy of HCC.

3 February 2025
Verified
Other
Open access
Giuseppe CabibboGiuseppe Cabibbo
Giuseppe Cabibbo
CCCiro Celsa
Ciro Celsa
SBSalvatore Battaglia
Salvatore Battaglia
MEMarco Enea
Marco Enea
GMGabriele Di Maria
Gabriele Di Maria
CCCalogero Cammà
Calogero Cammà
Supplementary Table 3. Rates of HCC radiological progression or clinical hepatic decompensation as first event.

3 February 2025
Verified
Other
Open access
Giuseppe CabibboGiuseppe Cabibbo
Giuseppe Cabibbo
CCCiro Celsa
Ciro Celsa
SBSalvatore Battaglia
Salvatore Battaglia
MEMarco Enea
Marco Enea
GMGabriele Di Maria
Gabriele Di Maria
CCCalogero Cammà
Calogero Cammà
Supplementary Figure S1. Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with systemic therapy at highest risk of death. Clinical hepatic decompensation is associated with higher hazard ratio for death, compared to HCC radiological progression. Albumin-bilirubin (ALBI) grade, INR and macrovascular invasion are independent predictors of clinical hepatic decompensation.

11 November 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SBSalvatore Battaglia
Salvatore Battaglia
MAMassimo Attanasio
Massimo Attanasio
SASabrina Arnone
Sabrina Arnone
AGAgostino Geraci
Agostino Geraci
GMGiuseppe Murolo
Giuseppe Murolo
MEMarco Enea
Marco Enea
Background: Emergency department (ED) overcrowding has increased worldwide in recent years. This paper provides quantitative information based on data collected immediately before the COVID-19 outbreak, which can serve as a baseline for developing systematic approaches to prolonged length of stay (LoS) in EDs. Materials and methods: We analysed a random sample of 10,077 ED accesses drawn from the 503,797 eligible accesses recorded in 2019 in the 16 largest hospitals of Sicily, Italy. LoS was modelled using a cause-specific competing-risks Cox frailty model with Discharge and Hospitalization as competing endpoints. Two log-normal frailty components were included to account for unobserved heterogeneity between EDs and between patients. Non-proportionality was addressed by stratifying on pathology and by including time-varying effects for triage. Cumulative incidence functions (CIFs) were computed to estimate the probability of each endpoint and strata over time. Results: Median LoS was 1.70 hours for Discharge and 3.77 hours for Hospitalization, and the gap widened markedly in the upper tail (90th percentile: 7.10 vs 34.95 hours). Discharge was associated with pathology, age, triage, sex and season; Hospitalization with pathology, age, triage and season. The hazard of Discharge decreased by 2% per additional year of age (HR = 0.98, 95% CI 0.977–0.983) and was 10% higher for accesses in summer (HR = 1.10, 95% CI 1.03–1.16). The hazard of Hospitalization increased by 0.4% per year of age (HR = 1.004, 95% CI 1.001–1.007). The effect of triage was time-dependent: at 10 hours of LoS, red-coded accesses had a 69% lower hazard of Discharge (HR = 0.31) and a 53% higher hazard of Hospitalization (HR = 1.53) than other codes. Circulatory and respiratory diseases and blood diseases showed the highest CIFs for Hospitalization and prolonged LoS for both endpoints, whereas skin and musculoskeletal diseases, injuries and poisoning, and nervous system diseases showed the highest CIFs for Discharge. Conclusions: Prolonged LoS in Sicilian EDs was driven mainly by pathology, and the exit process differed systematically across disease groups: patients with circulatory and respiratory diseases and with blood diseases waited longest before both Discharge and Hospitalization.The large between-ED heterogeneity in the hazard of Hospitalization, indicates that admission delays reflect organisational as well as structural constraints. Interventions to reduce overcrowding — in particular any expansion of inpatient capacity — should therefore be targeted at the specific wards receiving these patients, rather than applied uniformly across the hospital.